Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.72
CDNA's Cash-to-Debt is ranked lower than
68% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.04 vs. CDNA: 0.72 )
Ranked among companies with meaningful Cash-to-Debt only.
CDNA' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.33  Med: 0.72 Max: 3.17
Current: 0.72
0.33
3.17
Equity-to-Asset 0.25
CDNA's Equity-to-Asset is ranked lower than
76% of the 201 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.59 vs. CDNA: 0.25 )
Ranked among companies with meaningful Equity-to-Asset only.
CDNA' s Equity-to-Asset Range Over the Past 10 Years
Min: -15.26  Med: 0.25 Max: 0.68
Current: 0.25
-15.26
0.68
Piotroski F-Score: 3
Altman Z-Score: -4.96
Beneish M-Score: -3.20
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -91.88
CDNA's Operating Margin % is ranked lower than
71% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.12 vs. CDNA: -91.88 )
Ranked among companies with meaningful Operating Margin % only.
CDNA' s Operating Margin % Range Over the Past 10 Years
Min: -91.88  Med: -11.45 Max: 4.58
Current: -91.88
-91.88
4.58
Net Margin % -97.13
CDNA's Net Margin % is ranked lower than
72% of the 203 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.10 vs. CDNA: -97.13 )
Ranked among companies with meaningful Net Margin % only.
CDNA' s Net Margin % Range Over the Past 10 Years
Min: -97.14  Med: -24.74 Max: 2.86
Current: -97.13
-97.14
2.86
ROE % -143.47
CDNA's ROE % is ranked lower than
84% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. CDNA: -143.47 )
Ranked among companies with meaningful ROE % only.
CDNA' s ROE % Range Over the Past 10 Years
Min: -161.18  Med: -99.95 Max: -38.72
Current: -143.47
-161.18
-38.72
ROA % -51.42
CDNA's ROA % is ranked lower than
71% of the 219 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -3.30 vs. CDNA: -51.42 )
Ranked among companies with meaningful ROA % only.
CDNA' s ROA % Range Over the Past 10 Years
Min: -59.64  Med: -35.87 Max: 2.2
Current: -51.42
-59.64
2.2
ROC (Joel Greenblatt) % -1294.07
CDNA's ROC (Joel Greenblatt) % is ranked lower than
85% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.22 vs. CDNA: -1294.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CDNA' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -1394.03  Med: -110.58 Max: 71
Current: -1294.07
-1394.03
71
GuruFocus has detected 4 Warning Signs with CareDx Inc $CDNA.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CDNA's 10-Y Financials

Financials (Next Earnings Date: 2017-08-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CDNA Guru Trades in Q1 2016

Chuck Royce 85,917 sh (+15.46%)
» More
Q2 2016

CDNA Guru Trades in Q2 2016

Chuck Royce 134,745 sh (+56.83%)
» More
Q3 2016

CDNA Guru Trades in Q3 2016

Chuck Royce 247,618 sh (+83.77%)
» More
Q4 2016

CDNA Guru Trades in Q4 2016

Chuck Royce 426,361 sh (+72.18%)
» More
» Details

Insider Trades

Latest Guru Trades with CDNA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 325413    SIC: 8071
Compare:OTCPK:GNWSF, NAS:ROKA, NAS:BIOP, OTCPK:ILIU, OTCPK:EXDI, NAS:GENE, OTCPK:CRRVF, NAS:IDXG, OTCPK:MYAN, NAS:CBMX, OTCPK:MNLIF, OTCPK:LXXGF, OTCPK:MHTX, NAS:TEAR, OTCPK:SQIDF, OTCPK:TDSGF, NAS:WGBS, NAS:DRIO, OTCPK:TBIO, NAS:BASI » details
Headquarter Location:USA
CareDx Inc is a commercial stage company. The Company develops, markets and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient's lifetime.

CareDx Inc was incorporated in the State of Delaware on December 21, 1998 as Hippocratic Engineering, Inc. In April 1999, the Company changed its name to BioCardia, Inc., in June 2002 to Expression Diagnostics, Inc., in July 2007 to XDx, Inc. and in March 2014 to CareDx, Inc. The Company completed its initial public offering on July 22, 2014. The Company is a commercial stage company. The Company is engaged in developing, marketing and delivers a diagnostic surveillance solution for heart transplant recipients to help clinicians make personalized treatment decisions throughout a transplant patient's lifetime. The Company's commercialized testing solution, the AlloMap heart transplant molecular test (AlloMap), an FDA-cleared test, is a blood-based test used to monitor for acute cellular rejection in heart transplant recipients. AlloMap uses gene expression technology to aid in the identification of heart transplant recipients at low risk of rejection. It provides a single integer score ranging from 0 to 40 and determines the probability of moderate to severe acute cellular rejection. It can be used for heart transplant recipients 15 years of age or older 55 days post-transplant. The Company is also engaged in developing additional testing solutions in the heart transplant market and new testing solutions in other organ transplant markets. It is engaged in applying next generation sequencing platforms to detect and quantitate genetic differences between cell-free DNA (cfDNA) in the blood stream emanating from the donor heart and cfDNA emanating from the transplant recipient. The Company markets AlloMap to healthcare providers through its direct sales force that targets transplant centers and their physicians, coordinators and nurse practitioners. The Company has 16 issued United States patents, one pending United States patent application, and three pending patent applications outside the United States related to transplant. Its solution for heart transplant recipients competes against existing diagnostic tests utilized by pathologists, which, in the case of heart transplant rejection, generally involve evaluating biopsy. It operations are subjects to a variety of federal, state and local environmental and safety laws and regulations.

Top Ranked Articles about CareDx Inc

CareDx to Present Key AlloSure Validation Data at ATC
CareDx Appoints Michael Bell as Chief Financial Officer
CareDx Announces Receipt of Expected Letter from Nasdaq
CareDx to Present New Data on AlloMap and AlloSure at ISHLT
CareDx Closes New $25 Million Debt Facility

Interest-only through February 2018

BRISBANE, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it has signed a $25 million long-term debt agreement with an institutional investor, with all $25 million funded upfront.  
This new facility consists of $27.78 million in convertible notes with a maturity date of February 28, 2020, an interest rate of 9.5% per annum payable monthly, and is convertible into the Company’s common stock at a price of $4.56 per share at JGB’s option.  The proceeds from this new facility will be used to pay off the Company's current $11.2 million debt facility with East West Bank and provide additional funding for growth initiatives, including the proposed launch of AlloSure.  Following the East West Bank pay off, CareDx will have cash and cash equivalents of approximately $21.6 million, including restricted cash of $9.375 million.  Under the existing East West Bank facility, CareDx is required to make principal payments through the end of the agreement in December 1, 2018. With this new agreement with the institutional investor, the Company will make interest-only payments on the debt through February 2018. Craig-Hallum Capital Group LLC served as exclusive placement agent in connection with the transaction. "We are pleased to have secured this facility providing us with liquidity enhancement," said Peter Maag, CareDx President and Chief Executive Officer. "This new agreement will also provide the Company with additional capital as we continue launch AlloSure and strengthen operations across the Company." The agreement is a senior secured facility and calls for covenants, including additional debt and cash maintenance covenants.  Beginning in March 2018, the institutional investor can, at its option require the company to repay up to $937,500 of the facility per month. These repayments can be honored in cash or, subject to certain limitations, Company stock at the Company’s election. As part of the new debt facility, the Company will issue to the institutional investor 1,250,000 warrants to purchase shares of common stock.  The warrants are exercisable 185 days from their grant date through their 5.5 year term at $5.00 per share. Further information with respect to the new debt facility is contained in a Current Report on Form 8-K filed today by CareDx with the Securities and Exchange Commission. About CareDx CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. CareDx offers AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection (ACR). CareDx is developing additional products for transplant monitoring using a variety of technologies, including AlloSure®, a proprietary next-generation sequencing–based test to detect donor-derived cell-free DNA (dd-cfDNA) after transplantation. CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP® is a set of HLA typing products used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation. XM-ONE® is the first standardized test that quickly identifies a patient’s antigens against HLA Class I, Class II or antibodies against a donor’s endothelium. For more information, please visit: www.CareDx.com. Forward Looking Statements In addition to historical information, this press release contains forward-looking statements with respect to our business, research, development and commercialization efforts, our proposed use of proceeds from the financing and our prospects. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including  our diagnostic studies, including obtaining sufficient clinical samples and participation of clinical investigators in such studies, the timeline for completion of research efforts, development and commercialization of additional diagnostic solutions including cell-free DNA, which is a lengthy and complex process that may not be successful, our dependence on Medicare for a substantial portion of our revenue, and our dependence on health insurers and other third-party payers to provide coverage for our current test and future tests, if any.  These factors, together with those that are described in our filings with the SEC, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, and the Annual Report on Form 10-K for the year ended December 31, 2015 as filed by us with the SEC, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Investor Contact
Jamar Ismail, Vice President
Westwicke Partners, LLC 
T:  1 415-513-1282
E:  [email protected]

Read more...
CareDx Reports Preliminary Fourth Quarter and FY 2016 Financial Results

Company to host conference call today at 5:00pm ET

BRISBANE, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported preliminary financial results for the fourth quarter and year ended December 31, 2016.
Recent highlights:  Continued to grow revenues on its core products and consolidated recent acquisition Reported record FY 2016 preliminary revenues in the range of $40.4M to $40.7MAchieved total preliminary revenue for the fourth quarter of 2016 in the range of $10.6M to $10.9M AlloMap® preliminary revenues were $7.2M to $7.4M in the quarter, with quarterly US tests volume up by 5.5% year-over-yearOlerup® preliminary revenues contributed $3.4M to $3.5M in the fourth quarter Advanced AlloSure® clinical data to support reimbursement and future adoption AlloSure DART study shows that the testing service identifies active organ rejectionAlloSure clinical data featured in two leading scientific journals Acquired SBT Resolver™ HLA Typing Products from Illumina, adding to a source of growthCompleted convertible debt financing with $25M funded Financing provides launch funding for AlloSure with interest-only period through February 2018 "Driving AlloSure toward commercialization is our top priority and we believe this will make a fundamental difference for kidney transplant patients and generate shareholder value. This quarter we demonstrated that we are delivering on our commitment to bring next generation sequencing solutions to the transplant clinic. We have submitted the AlloSure dossier for reimbursement with Medicare," said Peter Maag, CareDx President and Chief Executive Officer. “With clarity on AlloMap reimbursement in the Clinical Lab Fee Schedule, we also secured funding that helps to launch AlloSure and drive product growth.” Preliminary Full Year and Fourth Quarter 2016 Financial Results
These financial results for the year and three months ended December 31, 2016 are preliminary and will be updated with the filing of the upcoming Annual Report on Form 10-K for the year ended December 31, 2016. Preliminary revenue for the year and three months ended December 31, 2016, were in the ranges of $40.4 million to $40.7 million and $10.6 million to $10.9 million, respectively, compared with $28.1 million and $6.6 million in corresponding periods of 2015, respectively; and reflected the contribution of Olerup branded product sales following the acquisition of Allenex AB in April 2016. Preliminary revenue from AlloMap tests for the year and three months ended December 31, 2016, were in the ranges of $29.5 million to $29.7 million and $7.2 million to $7.4 million, respectively, compared with $27.9 million and $6.7 million in the corresponding periods of 2015, respectively. Olerup revenue in year and three months ended December 31, 2016, were in the ranges of $10.6 million to $10.7 million and $3.4 million to $3.5 million, respectively.    For the year ended December 31, 2016, the preliminary net result was in a loss range of $41.9 million to $39.3 million compared to a net loss of $13.7 million in 2015. For the three months ended December 31, 2016, the preliminary net result was in a loss range of $17.9 million to $15.3 million compared to a net loss of $4.8 million in the same period of 2015. In the three months ended December 31, 2016, the Company recorded an impairment of goodwill recorded in the acquisition of Allenex AB in the range of $12.8 million to $14.9 million. Reflected in the Company’s results for the three months ended December 31, 2016, is a net other income of $0.7 million connected with the settlement of legal matters with Oberland Capital and the Nasdaq Stockholm. 2017 Guidance
For the full year 2017, the Company expects revenue to be in the range of $45 million to $50 million, excluding any potential AlloSure revenue. The Company has filed for coverage and reimbursement with the MolDx program at Palmetto and the dossier is currently under technical review. Debt Financing
Today, the Company announced that it has signed and closed a senior secured convertible note agreement with an institutional investor, with $25.0 million funded. This new facility consists of $27.78 million in convertible notes with a maturity date of February 28, 2020, an interest rate of 9.5% per annum payable monthly, and is convertible into the Company’s common stock at a price of $4.56 per share at the investor’s option. The new facility requires interest-only payments through February 2018.  Commencing in March 2018, the investor may require the Company to repay up to $937,500 of the facility per calendar month. The Company will have the option to make such payments in cash or, subject to certain limitations, shares of its common stock.  The proceeds from this new facility will be used to retire the Company's remaining outstanding debt with East West Bank and provide additional funding for the AlloSure launch initiatives. Conference Call
Management will host a conference call today beginning at 2:00 pm PT/5:00 pm ET.  Individuals interested in listening to the conference call may do so by dialing (855) 420-0616 for domestic callers or (678) 304-6848 for international callers. Please reference Conference ID: 88559794. To listen to a live webcast, please visit the investor relations section of CareDx's website at: www.CareDx.com. A replay of the call will be available beginning March 15, 2017 at 5:00 pm PT/8:00 pm ET through 5:00 pm PT/8:00 pm ET on March 16, 2017. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 88559794. The webcast will also be available on CareDx's website for one year following the completion of the call. About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a global molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients. CareDx offers AlloMap®, a gene expression test that aids clinicians in identifying heart transplant patients with stable graft function who have a low probability of moderate to severe acute cellular rejection (ACR). CareDx is developing additional products for transplant monitoring using a variety of technologies, including AlloSure®, a proprietary next-generation sequencing–based test to detect donor-derived cell-free DNA (dd-cfDNA) after transplantation. CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. Olerup SSP® is a set of HLA typing products used prior to hematopoietic stem cell/bone marrow transplantation and organ transplantation. XM-ONE® is the first standardized test that quickly identifies a patient’s antigens against HLA Class I, Class II or antibodies against a donor’s endothelium. For more information, please visit: www.CareDx.com. Forward Looking Statements
In addition to historical information, this press release contains forward-looking statements with respect to our business, research, development and commercialization efforts, anticipated future financial results, including our guidance for full fiscal 2017 revenue, and preliminary financial results for the three months and year ended December 31, 2016, which final results could change materially, our proposed use of proceeds from the financing with the institutional investor described above and our prospects. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks related to our diagnostic studies, including obtaining sufficient clinical samples and participation of clinical investigators in such studies, the timeline for completion of research efforts, development and commercialization of additional diagnostic solutions including cell-free DNA, which is a lengthy and complex process that may not be successful, our dependence on Medicare for a substantial portion of our revenue, our dependence on health insurers and other third-party payers to provide coverage for our current test and future tests, if any, our intellectual property position, and completion of the audit of our financial statements for the year ended December 31, 2016.  These factors, together with those that are described in our filings with the Securities and Exchange Commission (SEC), including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2016, and the Annual Report on Form 10-K for the year ended December 31, 2015, as amended, as filed by us with the SEC, may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. The Company expressly disclaims any obligation or undertaking, except as required by law, to update or revise any such forward-looking statements.
Investor Contact
Jamar Ismail, Vice President
Westwicke Partners, LLC 
T:  1 415-513-1282
E:  [email protected]

Read more...
AlloSure Featured in Journal of Applied Laboratory Medicine

Defines Cell-free DNA Levels in Stable Kidney Transplant Patients

BRISBANE, Calif., March 14, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients, announces a publication in the Journal of Applied Laboratory Medicine. This report describes the biological variation and clinical reference intervals of donor-derived cell-free DNA (dd-cfDNA) in stable healthy renal transplant recipients. 
Lead author Dr. Jonathan S. Bromberg, Vice Chair Research at the University of Maryland, School of Medicine, stated, “This report for the first time establishes the biological variation and reference intervals for the AlloSure® test in a population of clinically stable renal transplant recipients. The biological variability of the test in a reference renal transplant population is critical to the clinical interpretation of results in allograft recipients, who may undergo serial monitoring of dd-cfDNA to assess the status of the allograft.”  Key Findings: Stable, healthy renal transplant recipients have a median AlloSure level of 0.21%.96% of AlloSure results for stable, healthy renal transplant patients are below 1% dd-cfDNA.The reference change value RCV(%), for AlloSure is 61. This reference change value defines the relative change, between two sequential results from an individual that may be considered clinically significant. This reference population was selected from the cohort of subjects enrolled in the DART study (Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Acute Rejection in Kidney Transplant Recipients, NCT02424227) Rigorous demonstration of the assay analytical variation of the clinical-grade AlloSure assay used in this study was critical to these findings. James P. Yee M.D., Ph.D., Chief Medical Officer at CareDx, Inc. said, “This report is important for the clinical interpretation of AlloSure test results as it assists clinicians to stratify their patients, and manage their care accordingly.  The AlloSure level offers a new criterion that clinicians may consider in addition to other conventional factors used to make decisions regarding immunosuppressive medications in individual renal transplant patients.” The link to the publication: http://jalm.aaccjnls.org/content/early/2017/03/13/jalm.2016.022731 NOTES FOR CITATION OF PUBLICATION “Biological Variation of Donor-derived Cell-free DNA in Renal Transplant Recipients: Clinical Implications” by Jonathan S. Bromberg, Daniel C. Brennan, Emilio Poggio, Suphamai Bunnapradist, Anthony Langone, Puneet Sood, Arthur J. Matas, Shikha Mehta, Asif Sharfuddin, Bernard Fischbach, Mohanram Narayanan, Stanley C. Jordan, David J. Cohen, Ziad S. Zaky, David Hiller, Robert N. Woodward, Marica Grskovic, John J. Sninsky, James P. Yee, and Roy D. Bloom. Accepted, in press in The Journal of Applied Laboratory Medicine Feb 2017.  Published by American Association for Clinical Chemistry. ABOUT THE JOURNAL OF Applied Laboratory Medicine: The Journal of Applied Laboratory Medicine (JALM) is an international, peer-reviewed AACC publication that showcases clinically relevant laboratory topics in applied and translational research, and thoughtful commentary on the practice of clinical chemistry and laboratory medicine. Through JALM the AACC aims to provide a resource to laboratory professionals and the healthcare team for discovering new adaptive solutions for meeting patient care challenges and driving innovation in the field of laboratory medicine.  JALM also aims to provide Laboratory professionals and the healthcare team with interpretive guidance so that patients receive the most effective care available.  As such, JALM focuses on cutting edge research in applied and translational laboratory medicine.  JALM will consider submissions for publication on laboratory methods, evidence-based laboratory medicine, flow cytometry, hemostasis, management, health economics, best practices, test utilization, critical care, and pediatric testing. Additionally, the journal will provide a forum for discussion of policy and regulatory issues that impact the field. About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients.  CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. For more information, please visit: www.CareDx.com.   Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts including, but not limited to the development, commercialization, utility, performance and adoption of AlloSure. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risk associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by us with the SEC on March 29, 2016 and the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016 filed by us with the SEC on November 14, 2016.  Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Contact
Sasha King, Head of Marketing
T: 1 415-287-2393
E: [email protected]

Read more...
AlloSure Featured in Journal of the American Society of Nephrology

Cell-free-DNA test identifies active rejection in kidney transplant patients

BRISBANE, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- CareDx, Inc. (NASDAQ:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant recipients, announces a ground-breaking publication:
A new report in the Journal of the American Society of Nephrology describes the performance of AlloSure®, a method of measuring donor-derived cell-free DNA (dd-cfDNA) in the blood of renal transplant recipients.  Increased levels of dd-cfDNA detected using AlloSure are associated with active rejection of the allograft.  Accurate and timely detection of allograft rejection and effective treatment are essential for long-term survival of renal transplants. “The DART study evidence suggests that AlloSure, a non-invasive blood test, may enable more frequent, quantitative, and safer assessment of allograft rejection and injury. AlloSure, as part of a surveillance strategy, could help identify patients with ongoing organ injury,” explains principal investigator, Daniel C. Brennan, M.D. at the Division of Nephrology, Washington University School of Medicine in St. Louis. To investigate the use of AlloSure as a surveillance tool, the authors prospectively collected blood specimens from renal transplant patients at scheduled intervals and at the time of clinically indicated biopsies. Key Findings of the Study: AlloSure provides clear stratification of patients for probability of rejection
  - Active rejection patients showed median AlloSure levels at 1.6%
  - Antibody- mediated rejection patients showed median AlloSure levels at 2.9%
  - Non-rejection patients showed median AlloSure levels of 0.21%AlloSure was superior to serum creatinine in identifying which patients had active rejectionStudy centers applied different protocols of use and frequency of renal biopsies Roy D.  Bloom, M.D.,  Medical Director of Renal Transplantation at University of  Pennsylvania Health System stated, “This is the first report to establish clinical performance characteristics for this emerging molecular biomarker in renal transplant patients with a now validated assay of dd-cfDNA in the largest (N =398 patients) prospective, multicenter observational study of dd-cfDNA.  The study population is representative of the spectrum renal transplant recipients in the United States. We applied the Banff working group’s international histopathology classification criteria to establish the reference cases of rejection. Elevations in AlloSure were found to be strongly correlated with active rejection, especially with antibody-mediated rejection (ABMR).” ABMR is increasingly recognized as the form of immune-mediated injury causing long-term graft loss. James P. Yee M.D., Ph.D., Chief Medical Officer at CareDx, Inc. commented, "We’re excited with this first publication from the DART study which clinically validates the performance of AlloSure. With this test, CareDx has delivered on its promise to provide a blood-based test that measures dd-cfDNA in transplantation to identify patients with active rejections. This progress was made possible by excellent collaboration from 14 major renal transplant centers and their patients who volunteered to participate in the study.” Here is a link to the abstract online: http://jasn.asnjournals.org/content/early/2017/03/08/ASN.2016091034.abstract NOTES FOR CITATION
“Cell-free DNA and Active Rejection in Kidney Allografts”,  by Roy D. Bloom, Jonathan S. Bromberg,  Emilio Poggio,  Suphamai Bunnapradist, Anthony Langone, Puneet Sood,  Arthur Matas, Shikha Mehta, Roslyn B. Mannon, Asif Sharfuddin, Bernard Fischbach, Mohanram Narayanan, Stanley Jordan, David Cohen, Matthew Weir, David Hiller, Preethi Prasad, Robert N. Woodward, Marica Grskovic, John Sninsky, James P. Yee, and Daniel C. Brennan, for the Circulating Donor-Derived Cell-Free DNA in Blood for Diagnosing Active Rejection in Kidney Transplant Recipients (DART) Study Investigators.  (DOI: 10.1681/ASN.2016091034), published online in advance of the Journal of the American Society of Nephrology, Volume 28, 2017.  About the Journal of the American Society of Nephrology:
The Journal of the American Society of Nephrology (Print ISSN: 1046-6673; Online ISSN: 1533-3450) is an official publication of the American Society of Nephrology. JASN publishes highly competitive original manuscripts, brief reviews, and special articles in areas of basic and clinical science relevant to the broad discipline of nephrology. Subject matter appropriate for JASN includes, but is not restricted to, the following: cell biology; developmental biology; genetics; cell and transport physiology; hemodynamics and vascular regulation; immunology and pathology; pathophysiology of renal disease and progression; mineral metabolism and bone disease; clinical nephrology, epidemiology, and outcomes; dialysis; and transplantation. The editors encourage only the submission of meritorious research that will communicate important advances in the field of nephrology. The Journal of the American Society of Nephrology had an impact factor of 9.43 as of 2014. About CareDx
CareDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value, non-invasive diagnostic surveillance solutions for transplant recipients. The Company has commercialized AlloMap®, a gene expression test that aids clinicians in identifying heart transplant recipients.  CareDx is also pursuing the development of additional products for post-transplant monitoring of other solid organs that use a variety of technologies, including next generation sequencing, to detect donor-derived cell-free DNA to monitor the health of organs after transplantation. CareDx, with its presence through Olerup, also develops, manufactures, markets and sells high quality products that increase the chance of successful transplants by facilitating a better match between a donor and a recipient of stem cells and organs. For more information, please visit: www.CareDx.com.   Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts including, but not limited to the development, commercialization, utility, performance and adoption of AlloSure. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risk associated with successful research, development and planned commercialization of our technologies, that are described in our filings with the SEC, including the Annual Report on Form 10-K for the fiscal year ended December 31, 2015 filed by us with the SEC on March 29, 2016 and the Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2016 filed by us with the SEC on November 14, 2016.  Any of these may cause our actual results, performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
Contact
Sasha King, Head of Marketing
T: 1 415-287-2393
E: [email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 0.95
CDNA's PB Ratio is ranked higher than
95% of the 196 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.69 vs. CDNA: 0.95 )
Ranked among companies with meaningful PB Ratio only.
CDNA' s PB Ratio Range Over the Past 10 Years
Min: 0.83  Med: 2.13 Max: 3.44
Current: 0.95
0.83
3.44
PS Ratio 0.33
CDNA's PS Ratio is ranked higher than
92% of the 195 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.36 vs. CDNA: 0.33 )
Ranked among companies with meaningful PS Ratio only.
CDNA' s PS Ratio Range Over the Past 10 Years
Min: 0.29  Med: 1.99 Max: 3.9
Current: 0.33
0.29
3.9
EV-to-EBIT -1.07
CDNA's EV-to-EBIT is ranked lower than
99.99% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.08 vs. CDNA: -1.07 )
Ranked among companies with meaningful EV-to-EBIT only.
CDNA' s EV-to-EBIT Range Over the Past 10 Years
Min: -24.7  Med: -2.4 Max: 1730
Current: -1.07
-24.7
1730
EV-to-EBITDA -1.16
CDNA's EV-to-EBITDA is ranked lower than
99.99% of the 198 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 17.34 vs. CDNA: -1.16 )
Ranked among companies with meaningful EV-to-EBITDA only.
CDNA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -33.2  Med: -2.5 Max: 91.8
Current: -1.16
-33.2
91.8
Current Ratio 0.65
CDNA's Current Ratio is ranked lower than
92% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. CDNA: 0.65 )
Ranked among companies with meaningful Current Ratio only.
CDNA' s Current Ratio Range Over the Past 10 Years
Min: 0.65  Med: 1.18 Max: 3.62
Current: 0.65
0.65
3.62
Quick Ratio 0.52
CDNA's Quick Ratio is ranked lower than
91% of the 209 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.15 vs. CDNA: 0.52 )
Ranked among companies with meaningful Quick Ratio only.
CDNA' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 1.09 Max: 3.56
Current: 0.52
0.52
3.56
Days Inventory 79.20
CDNA's Days Inventory is ranked higher than
51% of the 171 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.87 vs. CDNA: 79.20 )
Ranked among companies with meaningful Days Inventory only.
CDNA' s Days Inventory Range Over the Past 10 Years
Min: 21.99  Med: 25.79 Max: 79.2
Current: 79.2
21.99
79.2
Days Sales Outstanding 24.87
CDNA's Days Sales Outstanding is ranked higher than
73% of the 172 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 62.33 vs. CDNA: 24.87 )
Ranked among companies with meaningful Days Sales Outstanding only.
CDNA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 16.99  Med: 30.7 Max: 37.49
Current: 24.87
16.99
37.49
Days Payable 52.96
CDNA's Days Payable is ranked higher than
63% of the 161 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 53.45 vs. CDNA: 52.96 )
Ranked among companies with meaningful Days Payable only.
CDNA' s Days Payable Range Over the Past 10 Years
Min: 24.85  Med: 48.21 Max: 58.41
Current: 52.96
24.85
58.41

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.17
CDNA's Price-to-Median-PS-Value is ranked higher than
92% of the 170 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. CDNA: 0.17 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CDNA' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.14  Med: 1.36 Max: 1.37
Current: 0.17
0.14
1.37
Earnings Yield (Greenblatt) % -93.37
CDNA's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 297 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.45 vs. CDNA: -93.37 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CDNA' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -104.21  Med: 2.5 Max: 3.9
Current: -93.37
-104.21
3.9

More Statistics

Revenue (TTM) (Mil) $40.63
EPS (TTM) $ -2.62
Short Percentage of Float1.95%
52-Week Range $0.76 - 6.08
Shares Outstanding (Mil)21.39
» More Articles for CDNA

Headlines

Articles On GuruFocus.com
CareDx to Present Key AlloSure Validation Data at ATC Apr 28 2017 
CareDx Appoints Michael Bell as Chief Financial Officer Apr 21 2017 
CareDx Announces Receipt of Expected Letter from Nasdaq Apr 21 2017 
CareDx to Present New Data on AlloMap and AlloSure at ISHLT Apr 03 2017 
CareDx Closes New $25 Million Debt Facility Mar 15 2017 
CareDx Reports Preliminary Fourth Quarter and FY 2016 Financial Results Mar 15 2017 
AlloSure Featured in Journal of Applied Laboratory Medicine Mar 14 2017 
AlloSure Featured in Journal of the American Society of Nephrology Mar 09 2017 

More From Other Websites
CareDx to Present Key AlloSure Validation Data at ATC Apr 28 2017
ETFs with exposure to CareDx, Inc. : April 28, 2017 Apr 28 2017
CareDx, Inc. :CDNA-US: Earnings Analysis: Q4, 2016 By the Numbers : April 27, 2017 Apr 27 2017
CareDx reports 4Q loss Apr 21 2017
CareDx Appoints Michael Bell as Chief Financial Officer Apr 21 2017
CareDx Announces Receipt of Expected Letter from Nasdaq Apr 21 2017
CareDx Reports Fourth Quarter and Full Year 2016 Financial Results Apr 21 2017
CareDx to Present New Data on AlloMap and AlloSure at ISHLT Apr 03 2017
CareDx Reports Preliminary Fourth Quarter and FY 2016 Financial Results Mar 15 2017
CareDx Closes New $25 Million Debt Facility Mar 15 2017
AlloSure Featured in Journal of Applied Laboratory Medicine Mar 14 2017
AlloSure Featured in Journal of the American Society of Nephrology Mar 09 2017
ETFs with exposure to CareDx, Inc. : December 8, 2016 Dec 08 2016
ETFs with exposure to CareDx, Inc. : November 16, 2016 Nov 16 2016
CareDx, Inc. :CDNA-US: Earnings Analysis: Q3, 2016 By the Numbers : November 11, 2016 Nov 11 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)